Illuminating the <i>FGFR</i> fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications
Our findings offer critical novel insights into functional FGFR fusions and bear considerable clinical implications for identifying individuals whose tumors are most likely to respond favorably to FGFR-targeted therapies.
Authors
- Zhengchuang Liu
- Baoming Wang (ORCID: https://orcid.org/0000-0002-3154-1665)
- Tonghui Ma (ORCID: https://orcid.org/0000-0002-5414-0522)
- Qiong Yang (ORCID: https://orcid.org/0000-0002-5713-7484)
- Min Lyu (ORCID: https://orcid.org/0000-0002-0501-0940)
- Wei Li (ORCID: https://orcid.org/0000-0001-9931-5990)
- Zhuo Liu (ORCID: https://orcid.org/0000-0001-8696-8722)
- Xiaojuan Wang (ORCID: https://orcid.org/0000-0002-2617-6317)
- Jie Zhang (ORCID: https://orcid.org/0000-0001-6795-8000)
- Jianhua Zhu (ORCID: https://orcid.org/0000-0003-4169-6019)
- Yong Shao (ORCID: https://orcid.org/0000-0001-6591-8072)
- Chunyang Wang (ORCID: https://orcid.org/0000-0003-0343-2282)
- Yuping Zhu
- Dandan Zhao (ORCID: https://orcid.org/0009-0008-4902-3349)
- Jinhua Tao
- Zhenyuan Qian
- Yanxiang Zhang
Institutions
- Fundación Juan March (ES)
- Jilin University (CN)
- Chinese Academy of Sciences (CN)
- Zhejiang Cancer Hospital (CN)
- Wisdom Health (United States) (US)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Hangzhou DAC Biotech (China) (CN)
- Jilin Agricultural University (CN)
- Hangzhou Medical College (CN)
- Zygo (United States) (US)
- China Jiliang University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1093/oncolo/oyaf347
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00